Slide 1: Investor Presentation September 2022
Investor Presentation SEPTEMBER 2022
Slide 2: Disclaimer
2 © 2022 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward - looking statements .. These statements ar
Slide 3: oration ǀ Privileged, & Proprietary ǀ For Internal Use Only
3 © 2022 Glaukos Corporation 3 © 2021 Glaukos Corporation ǀ Privileged, Confidential & Proprietary ǀ For Internal Use Only
Slide 4: Attractive Financial Profile Provides Solid Foundation
4 © 2022 Glaukos Corporation Attractive Financial Profile Provides Solid Foundation SCALE MARGINS DIVERSIFICATION BALANCE SHEET $46 … 7 - Yr CAGR: 30% 2014 2021 TOTAL NET SALES ( in millions ) $294 2022 75% 83% 2014 1 FY2014 GAAP & non - GAAP gross margin (75%); 2Q 2022 GAAP gross margin of 75% was
Slide 5: 2022: Entering the Next Phase of Our Pioneering Journey
5 © 2022 Glaukos Corporation 2022: Entering the Next Phase of Our Pioneering Journey CORE FRANCHISES NEAR - TERM PIPELINE NEW R&D PLATFORMS & PROGRAMS GLOBAL ORGANIZATION Expanding Core Offering & Potential • Combo - cataract evolution • Standalone glaucoma entry • International glaucoma, iLink mark
Slide 6: Our Strategy for Long-Term Growth & Value Creation
6 © 2022 Glaukos Corporation 1 2 3 4 5 6 Novel Technology Platforms Leverageable Commercial Platform 1. SIGNIFICANT CLINICAL NEEDS 2. BIG IDEAS 3. SELF - FUNDING R&D HISTORICALLY 4. EFFICIENT COMMERCIAL CHANNEL 5. PROVEN MARKET CREATOR 6. OPERATIONAL EXCELLENCE Our Strategy for Long - Term Growth &
Slide 7: Big Ideas: Disrupting Legacy Topical Eye Drop Therapy
7 © 2022 Glaukos Corporation Big Ideas: Disrupting Legacy Topical Eye Drop Therapy Topical eye drops are often ineffective due to significant patient non - adherence • Complex dosing regimens that are difficult to follow • Forgetfulness • Instillation challenges • Impositions to quality of life • Oc
Slide 8: Our Novel Technology Platforms
8 © 2022 Glaukos Corporation Our Novel Technology Platforms 6+ programs with key regulatory milestones in 2022 R&D INVESTMENT SINCE 2018 350M + $ DISCLOSED PIPELINE PROGRAMS 14 2015 2022 4 5 technologically distinct platforms Pharma innovations dominate Advancing the standard of care across our 3 fr
Slide 9: Unique Features of Our Differentiated Platforms
9 © 2022 Glaukos Corporation All platforms disrupt traditional paradigms and are designed to generate multiple innovations that offer advantages over the current standards of care (not a single eye drop) Unique Features of Our Differentiated Platforms Pioneering firsts: Maximizing proven ability to
Slide 10: Designed to Generate Layers of Future Growth
10 © 2022 Glaukos Corporation 2021 2030+ US MARKET OPPORTUNITY 1 $2B $60B iAccess iPRIME iStent infinite iDose TR Epioxa (Epi - on) iLution Dry Eye iLution Presbyopia iDose TREX Retina XR: MKI iLink Third Gen Retina XR: Triamcinolone iDose ROCK iLution Blepharitis IOP Sensor + + + A decade - long ca
Slide 11: Delivered Through Our Leverageable Commercial Platform
11 © 2022 Glaukos Corporation Delivered Through Our Leverageable Commercial Platform 2014 2022 COUNTRIES WITH DIRECT SALES 2 17 $225 Efficient, scalable platform ready to provide a range of quality products and services across a growing global customer base NEAR - TERM PIPELINE PRODUCTS COMING INTO
Slide 12: iStent Platform: MIGS Pioneer & Innovation Leader
12 © 2022 Glaukos Corporation 1M+ iStent devices implanted worldwide iStent Platform: MIGS Pioneer & Innovation Leader PRODUCT/PROGRAM DISEASE STATUS iStent / iStent inject / iStent inject W Mild - to - Moderate Glaucoma with Cataract Approved (2012 / 2018 / 2020) iStent infinite Glaucoma (failed on
Slide 13: iAccess Launched in Q1 2022
13 © 2022 Glaukos Corporation iAccess ™ Launched in Q1 2022 iAccess is a precision blade designed to cut trabecular meshwork tissue, thereby allowing aqueous to flow directly into Schlemm’s canal Goniotomy with iAccess is designed to be unrestricted in its ability to create an extensive opening to S
Slide 14: iPRIME Launched in Q2 2022
14 © 2022 Glaukos Corporation iPRIME ™ Launched in Q2 2022 iPRIME is a minimally invasive viscoelastic delivery system that further supports the needs of physicians and patients This complementary technology further expands Glaukos’ broad portfolio of innovative ophthalmic solutions Commenced U.S co
Slide 15: iStent infinite: Powerful Standalone MIGS Indication
15 © 2022 Glaukos Corporation iStent infinite: Powerful Standalone MIGS Indication Three heparin - coated titanium stents preloaded into an auto - injection system that allows the surgeon to inject stents across a span of up to approximately six clock hours around Schlemm’s canal, the eye’s primary
Slide 16: iStent infinite: Powerful Standalone MIGS Indication
16 © 2022 Glaukos Corporation iStent infinite: Powerful Standalone MIGS Indication CLINICAL TRIAL RESULTS 1 76 of subjects achieved 20% or greater reduction in mean diurnal IOP from baseline on same or lower ocular hypotensive medication burden 13 ≥ 50 of subjects achieved 30% or greater reduction i
Slide 17: iDose Platform: The Next Stage in Glaucoma Therapy
17 © 2022 Glaukos Corporation iDose Platform: The Next Stage in Glaucoma Therapy PROGRAM DISEASE STATUS iDose TR OHT - Refractory Glaucoma Phase 3 iDose TREX OHT - Refractory Glaucoma Pre - clinical iDose Rock OHT - Refractory Glaucoma Pre - clinical DISCLOSED PIPELINE PROGRAMS Designed to address u
Slide 18: iDose TR: Phase 3 Trials Achieve Primary Efficacy Endpoints
18 © 2022 Glaukos Corporation IOP Reductions from Baseline (mmHg) 8.5 6.6 7.7 6.6 6.7 8.4 6.8 7.2 iDose TR: Phase 3 Trials Achieve Primary Efficacy Endpoints 1 mmHg range represents IOP reduction means across the six U.S. FDA pre - specified timepoints of 8AM and 10AM at Day 10, Week 6 a nd Month 3
Slide 19: iDose TR: Phase 3 Trial Highlights
19 © 2022 Glaukos Corporation Data suggest iDose TR may safely and effectively provide sustained dropless therapy to address patient non - adherence to and chronic side effects associated with topical glaucoma medications iDose TR: Phase 3 Trial Highlights iDose TR is not approved by the FDA In the
Slide 20: iDose TR: Phase 3 Trial Highlights
20 © 2022 Glaukos Corporation iDose TR: Phase 3 Trial Highlights iDose TR is not approved by the FDA As part of the Phase 3 trials, in - office administration of iDose TR was successfully employed with various subjects across multiple sites with outcomes that were consistent with the Phase 3 trials
Slide 21: iDose TR: Phase 2b Data at 36 Months
21 © 2022 Glaukos Corporation iDose TR is not approved by the FDA iDose TR: Phase 2b Data at 36 Months - 8.5 - 8.3 - 8.2 ~ 70% were responders well - controlled on iDose with the same or fewer topical IOP - lowering meds at 36 months vs screening Overall, iDose TR performed similarly to timolol at 3
Slide 22: iLink Platform: Bio-Activated Pharmaceuticals
22 © 2022 Glaukos Corporation iLink Platform: Bio - Activated Pharmaceuticals PRODUCT/ PROGRAM DISEASE STATUS Photrexa (Epi - off) Keratoconus Approved (2016) Epioxa (Epi - on) Keratoconus Phase 3 iLink Third - Generation Keratoconus Phase 2; actively enrolling COMMERCIAL PRODUCTS & DISCLOSED PIPELI
Slide 23: Epioxa (Epi-on): Phase 3 Trial Achieved Primary Efficacy Outcome
23 © 2022 Glaukos Corporation Epioxa (Epi - on): Phase 3 Trial Achieved Primary Efficacy Outcome - 1.0D Achieved primary efficacy outcome by demonstrating Kmax treatment effect of Well - tolerated procedure (majority of adverse events were mild and transient in nature; no change in corneal endotheli
Slide 24: iLution Platform: Transdermal Dropless Therapy
24 © 2022 Glaukos Corporation iLution Platform: Transdermal Dropless Therapy PROGRAM DISEASE STATUS iLution Dry Eye Dry Eye Phase 2: enrollment completed iLution Presbyopia Presbyopia Phase 2: enrollment completed iLution Blepharitis Demodex Blepharitis Pre - clinical Anterior Segment Candidates Gla
Slide 25: Retina XR Platform: Addressing Conventional Therapy Drawbacks
25 © 2022 Glaukos Corporation Retina XR Platform: Addressing Conventional Therapy Drawbacks PROGRAM DISEASE STATUS IVT Multi - Kinase Inhibitor AMD, DME Pre - clinical IVT Triamcinolone DME Pre - clinical DISCLOSED PIPELINE PROGRAMS Targeting biodegradable, small - molecule implant with 6 - 12 month
Slide 26: Retina XR Candidate: Multi-Kinase Inhibitor
26 © 2022 Glaukos Corporation Retina XR Candidate: Multi - Kinase Inhibitor FA LEAKAGE CHANGE FROM BASELINE IN MULTI - KINASE INHIBITOR CANDIDATE AND PLACEBO - TREATED DL - AAA EYES Leveraging 20+ years of injector system development expertise 0 28 56 84 112 140 168 196 224 252 280 0 10 20 30 40 Vas
Slide 27: Commercial Execution in the Areas Most Visible to Investors
27 © 2022 Glaukos Corporation Commercial Execution in the Areas Most Visible to Investors… Under the Surface: Photrexa (Epi - off) Combo - Cataract 30% 7 - Year CAGR Standalone Therapies
Slide 28: While Our Future is Just Beginning to Be Revealed
28 © 2022 Glaukos Corporation …While Our Future is Just Beginning to Be Revealed Photrexa (Epi - off) Combo - Cataract iLution OHT - Refractory Epioxa (Epi - on) Disruptive Programs For Glaucoma Dry Eye Presbyopia Keratoconus Blepharitis AMD, DME Photrexa (Epi - off) Combo - Cataract Epi - on, iDose
Slide 29: Summary: Glaukos is Different
29 © 2022 Glaukos Corporation Summary: Glaukos is Different Delivering disruptive dropless therapies designed to improve patient outcomes Five distinct technology platforms, dominated by pharmaceuticals and designed to generate waves of new market - expanding products Pursuing game - changing therap
Slide 30: Glaukos: Transforming Vision
GLAUKOS TRANSFORMING VISION
Slide 31: GAAP to Non-GAAP Reconciliation - 2Q 2022
31 © 2022 Glaukos Corporation Appendix Amort. of Stock-based Dev Tech Comp Exp on 2Q 2022 GAAP Intangibles Replacement 2Q 2022 Non-GAAP Gross Margin Awards Gross Margin Net Sales 72,685 $ 72,685 $ COGS 17,833 $ (5,523) $ (23) $ 12,287 $ Gross Profit 54,852 $ 5,523 $ 23 $ 60,398 $ Gross Margin 75% 83